NEW YORK (GenomeWeb) – Roche Diagnostic Canada said on Tuesday that Health Canada has approved the Cobas EGFR Mutation Test v2 for marketing in that country. 

The oncology assay is the first from Roche using either plasma or tumor tissue samples and identifies 42 mutations in the epidermal growth factor receptor gene, which the firm said is the most of any in vitro diagnostic on the market. It added that the assay can also be used to help select appropriate patients with non-small cell lung cancer for therapy with an EGFR tyrosine kinase inhibitor. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jul
24
Sponsored by
Qiagen

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Jul
25
Sponsored by
Streck

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms. 

Aug
09

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.